Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors
Primary Purpose
Metabolic Syndrome
Status
Completed
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Natural supplement containing chlorogenic acid and luteolin
Placebo (without any active ingredients)
Sponsored by
About this trial
This is an interventional supportive care trial for Metabolic Syndrome focused on measuring metabolic parameters, cardio-metabolic parameters
Eligibility Criteria
Inclusion Criteria:
- Men and women aged >18 years with the metabolic syndrome (as defined by the international criteria: Alberti KG, et al. Circulation. 2009; 120: 1640-5);
- BMI> 25 kg/m^2;
- Subjects able to swallow whole tablets;
- Informed consent obtained prior to any study-related activities.
Exclusion Criteria:
- Pregnancy or willingness to become pregnant;
- Severe liver dysfunction (ALT >2.5 times upper limit of normal);
- Severe renal failure (eGFR<60 mL/min/1.73 m2 using the MDRD formula);
- Severe infections at the discretion of the investigator (such as HIV, HBV and HCV);
- History or presence of malignant neoplasms within the last 5 years.
Sites / Locations
- University Hospital of Palermo
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Dietary Supplement
Placebo
Arm Description
50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
Outcomes
Primary Outcome Measures
Effect of natural supplement on metabolic parameters including body weight and Body Mass Index (BMI)
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including body weight (kg) and height (m) that will be combined to report BMI in kg/m^2.
Effect of natural supplement on metabolic parameters including waist circumference
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including waist circumference (cm).
Effect of natural supplement on metabolic parameters including plasma lipids
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol HDL-C) (mmol/l), while low-density lipoprotein cholesterol (LDL-C) will be calculated using the Friedewald formula.
Effect of natural supplement on metabolic parameters including glucose metabolism parameters
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma glycemia (mmol/l).
Effect of natural supplement on metabolic parameters including plasma insulinemia and HOMA (homeostatic model assessment) index
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma insulinemia (pmol/L) that with glycemia will be combined to report HOMA index.
Secondary Outcome Measures
Effect of natural supplement on cardio-metabolic parameters including plasma cytokines
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including plasma cytokines (inflammatory markers and adipokines) (pg/ml), that will be assessed using available enzyme-linked immunosorbent assay (ELISA) kits.
Effect of natural supplement on cardio-metabolic parameters including plasma lipoproteins
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including atherogenic lipoproteins as well as the analysis of the full spectrum of lipoprotein subclasses by gel electrophoresis.
Effect of natural supplement on cardio-metabolic parameters including subclinical atherosclerosis
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including subclinical atherosclerosis assessed by carotid intima-media thickness (CIMT) (mm).
Effect of natural supplement on cardio-metabolic parameters including fatty liver index
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including fatty liver index, a noninvasive method used for steatosis detection and quantification.
Full Information
NCT ID
NCT03444558
First Posted
June 5, 2017
Last Updated
October 23, 2018
Sponsor
University of Palermo
Collaborators
University of Catania
1. Study Identification
Unique Protocol Identification Number
NCT03444558
Brief Title
Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors
Official Title
Effect of a Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors in Patients With Metabolic Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
June 1, 2017 (Actual)
Primary Completion Date
February 28, 2018 (Actual)
Study Completion Date
February 28, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Palermo
Collaborators
University of Catania
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Clinical trial about beneficial effects of natural ingredient containing chlorogenic acid and luteolin on liver health and conditions related to liver (such as metabolic syndrome) for general body health.
Detailed Description
This is one randomized, double-blind, placebo-controlled study. The purpose of the present study is to evaluate and/or elucidate the role of the natural supplement, containing chlorogenic acid (10-12%) and luteinyl-7-glucoside (2-4%), on cardio-metabolic risk factors.
The research hypothesis is to evaluate whether natural supplement containing chlorogenic acid and luteolin (Puraltilix, BIONAP SRL, Catania, Italy) may improve several cardio-metabolic parameters in subjects with the metabolic syndrome.
All subjects will be evaluated at baseline and after 6 months of treatment (with natural supplement or placebo).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome
Keywords
metabolic parameters, cardio-metabolic parameters
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
placebo-controlled study
Masking
ParticipantInvestigator
Masking Description
double-blind study
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dietary Supplement
Arm Type
Experimental
Arm Description
50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
Intervention Type
Dietary Supplement
Intervention Name(s)
Natural supplement containing chlorogenic acid and luteolin
Intervention Description
50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
Intervention Type
Other
Intervention Name(s)
Placebo (without any active ingredients)
Intervention Description
50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
Primary Outcome Measure Information:
Title
Effect of natural supplement on metabolic parameters including body weight and Body Mass Index (BMI)
Description
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including body weight (kg) and height (m) that will be combined to report BMI in kg/m^2.
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on metabolic parameters including waist circumference
Description
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including waist circumference (cm).
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on metabolic parameters including plasma lipids
Description
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma lipids (total cholesterol, triglycerides, high-density lipoprotein cholesterol HDL-C) (mmol/l), while low-density lipoprotein cholesterol (LDL-C) will be calculated using the Friedewald formula.
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on metabolic parameters including glucose metabolism parameters
Description
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma glycemia (mmol/l).
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on metabolic parameters including plasma insulinemia and HOMA (homeostatic model assessment) index
Description
Effect of natural supplement containing chlorogenic acid and luteolin on metabolic parameters, including plasma insulinemia (pmol/L) that with glycemia will be combined to report HOMA index.
Time Frame
Change from baseline to 6 months of the supplementation
Secondary Outcome Measure Information:
Title
Effect of natural supplement on cardio-metabolic parameters including plasma cytokines
Description
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including plasma cytokines (inflammatory markers and adipokines) (pg/ml), that will be assessed using available enzyme-linked immunosorbent assay (ELISA) kits.
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on cardio-metabolic parameters including plasma lipoproteins
Description
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including atherogenic lipoproteins as well as the analysis of the full spectrum of lipoprotein subclasses by gel electrophoresis.
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on cardio-metabolic parameters including subclinical atherosclerosis
Description
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including subclinical atherosclerosis assessed by carotid intima-media thickness (CIMT) (mm).
Time Frame
Change from baseline to 6 months of the supplementation
Title
Effect of natural supplement on cardio-metabolic parameters including fatty liver index
Description
Effect of natural supplement containing chlorogenic acid and luteolin on cardio-metabolic parameters, including fatty liver index, a noninvasive method used for steatosis detection and quantification.
Time Frame
Change from baseline to 6 months of the supplementation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women aged >18 years with the metabolic syndrome (as defined by the international criteria: Alberti KG, et al. Circulation. 2009; 120: 1640-5);
BMI> 25 kg/m^2;
Subjects able to swallow whole tablets;
Informed consent obtained prior to any study-related activities.
Exclusion Criteria:
Pregnancy or willingness to become pregnant;
Severe liver dysfunction (ALT >2.5 times upper limit of normal);
Severe renal failure (eGFR<60 mL/min/1.73 m2 using the MDRD formula);
Severe infections at the discretion of the investigator (such as HIV, HBV and HCV);
History or presence of malignant neoplasms within the last 5 years.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manfredi Rizzo, MD, PhD
Organizational Affiliation
University Hospital of Palermo, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital of Palermo
City
Palermo
State/Province
Palrmo
ZIP/Postal Code
90127
Country
Italy
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
19805654
Citation
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. doi: 10.1161/CIRCULATIONAHA.109.192644. Epub 2009 Oct 5.
Results Reference
background
Learn more about this trial
Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors
We'll reach out to this number within 24 hrs